Known safety concerns, contraindications, and risk factors.
Inflammation-reduction peptide research is at an early, largely preclinical stage. No content here constitutes medical advice. Protocols should only be run under a qualified prescribing clinician using pharmaceutical-grade material.
Active or previous malignancy
Theoretical risk that regenerative and angiogenic effects could aid tumour cells. Generally contraindicated; coordinate with oncology before any use.
Pregnancy and breastfeeding
Insufficient human safety data. One animal study showed no teratogenicity for BPC-157 in pregnant rats, but no human validation.
Severe cardiovascular disease
ARA-290 specifically discouraged in severe CVD without strict medical supervision.
Neuroleptic, antidepressant, or stimulant therapy
BPC-157 modulates dopamine and serotonin pathways; theoretical interaction with psychiatric medications. Interaction data is extremely limited.